Literature DB >> 25012666

Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line.

Sakae Maeda1, Hiroshi Wada2, Yoko Naito3, Hiroaki Nagano2, Szandor Simmons4, Yoshinori Kagawa1, Atsushi Naito1, Junichi Kikuta4, Taeko Ishii3, Yoshito Tomimaru2, Naoki Hama2, Koichi Kawamoto2, Shogo Kobayashi2, Hidetoshi Eguchi2, Koji Umeshita2, Hideshi Ishii2, Yuichiro Doki2, Masaki Mori5, Masaru Ishii6.   

Abstract

Interferon-α (IFN-α) is used clinically to treat hepatocellular carcinoma (HCC), although the detailed therapeutic mechanisms remain elusive. In particular, IFN-α has long been implicated in control of the cell cycle, but its actual point of action has not been clarified. Here, using time lapse imaging analyses of the human HCC cell line HuH7 carrying a fluorescence ubiquitination-based cell cycle indicator (Fucci), we found that IFN-α induced cell cycle arrest in the G0/G1 phases, leading to apoptosis through an IFN-α type-2 receptor (IFNAR2)-dependent signaling pathway. Detailed analyses by time lapse imaging and biochemical assays demonstrated that the IFN-α/IFNAR2 axis sensitizes cells to apoptosis in the S/G2/M phases in preparation for cell death in the G0/G1 phases. In summary, this study is the first to demonstrate the detailed mechanism of IFN-α as an anticancer drug, using Fucci-based time lapse imaging, which will be informative for treating HCC with IFN-α in clinical practice.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apoptosis; Cell Cycle; Cell Death; Fucci; Hepatocellular Carcinoma; Interferon

Mesh:

Substances:

Year:  2014        PMID: 25012666      PMCID: PMC4156060          DOI: 10.1074/jbc.M114.551879

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Mechanisms of interferon-induced cell cycle arrest.

Authors:  O Sangfelt; S Erickson; D Grander
Journal:  Front Biosci       Date:  2000-04-01

2.  Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.

Authors:  D Murphy; K M Detjen; M Welzel; B Wiedenmann; S Rosewicz
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

Review 3.  The interferons: 50 years after their discovery, there is much more to learn.

Authors:  Sidney Pestka
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

4.  Mutational analysis of p73 and p53 in human cancer cell lines.

Authors:  H Yoshikawa; M Nagashima; M A Khan; M G McMenamin; K Hagiwara; C C Harris
Journal:  Oncogene       Date:  1999-06-03       Impact factor: 9.867

5.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes.

Authors:  M Dohn; S Zhang; X Chen
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

6.  TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria.

Authors:  Olav Gressner; Tobias Schilling; Katja Lorenz; Elisa Schulze Schleithoff; Andreas Koch; Henning Schulze-Bergkamen; Anna Maria Lena; Eleonora Candi; Alessandro Terrinoni; Maria Valeria Catani; Moshe Oren; Gerry Melino; Peter H Krammer; Wolfgang Stremmel; Martina Müller
Journal:  EMBO J       Date:  2005-06-09       Impact factor: 11.598

7.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

8.  Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.

Authors:  Hiroaki Nagano; Atsushi Miyamoto; Hiroshi Wada; Hideo Ota; Shigeru Marubashi; Yutaka Takeda; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

9.  Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor.

Authors:  F W Quelle; W Thierfelder; B A Witthuhn; B Tang; S Cohen; J N Ihle
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

10.  Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.

Authors:  Asako Sakaue-Sawano; Hiroshi Kurokawa; Toshifumi Morimura; Aki Hanyu; Hiroshi Hama; Hatsuki Osawa; Saori Kashiwagi; Kiyoko Fukami; Takaki Miyata; Hiroyuki Miyoshi; Takeshi Imamura; Masaharu Ogawa; Hisao Masai; Atsushi Miyawaki
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

View more
  19 in total

Review 1.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

2.  Heterogeneous nuclear ribonucleoprotein U-actin complex derived from extracellular vesicles facilitates proliferation and migration of human coronary artery endothelial cells by promoting RNA polymerase II transcription.

Authors:  Han Wang; Hengdao Liu; Xi Zhao; Xiaowei Chen
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.

Authors:  E Lau; J Sedy; C Sander; M A Shaw; Y Feng; M Scortegagna; G Claps; S Robinson; P Cheng; R Srivas; S Soonthornvacharin; T Ideker; M Bosenberg; R Gonzalez; W Robinson; S K Chanda; C Ware; R Dummer; D Hoon; J M Kirkwood; Z A Ronai
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

4.  High-throughput quantitative real-time RT-PCR assay for determining expression profiles of types I and III interferon subtypes.

Authors:  Lynnsey A Renn; Terence C Theisen; Maria B Navarro; Viraj P Mane; Lynnsie M Schramm; Kevin D Kirschman; Giulia Fabozzi; Philippa Hillyer; Montserrat Puig; Daniela Verthelyi; Ronald L Rabin
Journal:  J Vis Exp       Date:  2015-03-24       Impact factor: 1.355

5.  Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.

Authors:  João Paulo Portela Catani; Ruan F V Medrano; Aline Hunger; Paulo Del Valle; Sandy Adjemian; Daniela Bertolini Zanatta; Guido Kroemer; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Transl Oncol       Date:  2016-12       Impact factor: 4.243

6.  Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo.

Authors:  Shiyou Chen; Lunan Liang; Ying Wang; Jianhun Diao; Chunxiong Zhao; Gang Chen; Yunfeng He; Chunli Luo; Xiaohou Wu; Yao Zhang
Journal:  Mol Med Rep       Date:  2015-08-20       Impact factor: 2.952

7.  Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells.

Authors:  Hongmei Yin; Naifei Chen; Rui Guo; Hong Wang; Wei Li; Guanjun Wang; Jiuwei Cui; Haofan Jin; Ji-Fan Hu
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

8.  A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.

Authors:  Masafumi Yamashita; Hiroshi Wada; Hidetoshi Eguchi; Hisataka Ogawa; Daisaku Yamada; Takehiro Noda; Tadafumi Asaoka; Koichi Kawamoto; Kunihito Gotoh; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Int J Oncol       Date:  2016-04-25       Impact factor: 5.650

9.  Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients.

Authors:  Hang Yin; Cheng-Gong Liao; Jian-Guo Huang; Yong-Qiang Wang; Zheng Li; Lu-Lu Fan; Men-Long Qian; Nao Wan; Ning Lu
Journal:  Oncotarget       Date:  2017-06-19

Review 10.  Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.

Authors:  Li Zhang; Yu-Tzu Tai; Matthew Zhi Guang Ho; Lugui Qiu; Kenneth C Anderson
Journal:  Exp Hematol Oncol       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.